低剂量阿替普酶静脉溶栓治疗急性脑梗死的临床疗效和安全性

目的探讨低剂量阿替普酶(rt-pA)静脉溶栓治疗急性脑梗死的临床疗效和安全性。方法选取2016年9月~2018年9月收治的80例急性脑梗死患者为研究对象,将患者分为观察组与对照组,每组40例。将采用低剂量rt-pA静脉溶栓治疗的患者纳入观察组,采用标准剂量rt-pA静脉溶栓治疗的患者纳入对照组,对比两组临床疗效及安全性。结果观察组治疗有效率95.00%比对照组的治疗有效率80.00%显著提高(P<0.05);观察组并发症发生率2.50%,明显低于对照组的15.00%,差异有统计学意义(P<0.05)。结论针对急性脑梗死患者,使用低剂量rt-pA静脉溶栓治疗能取得良好的治疗效果,且并发症少,安全性更高。

The clinical efficacy and safety of intravenous thrombolysis with low-dose ateplase in the treatment of acute cerebral infarction

Objective To investigate the clinical efficacy and safety of intravenous thrombolysis with low-dose ateplase(rt-pA)in the treatment of acute cerebral infarction.Methods A total of 80 patients with acute cerebral infarction were selected and divided into observation group and control group from September 2016 to September 2018.The patients treated with low-dose rt-pA intravenous thrombolysis were included in the observation group.The patients treated with standard dose of rt-pA were used for intravenous thrombolysis.The clinical efficacy and safety of the 2 groups were compared.Results The treatment efficiency of the observation group(95.00%)was significantly higher than that of the control group(80.00%)(P<0.05).The incidence of complications in the observation group was 2.50%,which was significantly lower than that in the control group(15.00%,P<0.05).Conclusion For patients with acute cerebral infarction,intravenous thrombolytic therapy with low dose of rt-pA can achieve good therapeutic effect,with fewer complications and better safety,which is worthy of clinical reference and application.